Edward J ( Ed ) Radlo - IPWatchdog com | Patents & Intellectual Property Law ipwatchdog.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ipwatchdog.com Daily Mail and Mail on Sunday newspapers.
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumorPivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented.
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumorPivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented efficacy
Royalty Pharma plc (RPRX) announced Tuesday that it has acquired an interest in Agios Pharmaceuticals' (AGIO) royalty on Servier's vorasidenib for $905 million in upfront cash.